Good afternoon, and welcome to Synthetic Biologics 2019 First Quarter Investor Conference Call. [Operator Instructions] Please note, this event is being recorded. At this time, I would like to turn the call over to Vincent Perrone, Director, Corporate Communication, at Synthetic Biologics. Please go ahead.

Thank you, Debbie, and good afternoon, everyone. Welcome to Synthetic Biologics 2019 first quarter investor conference call. Today, I am joined by our Chief Executive and Financial Officer, Steven Shallcross; Dr. Michael Kaleko, Senior Vice President, Research and Development; and Dr. Vince Wacher, Head of Product and Corporate Development. Synthetic Biologics issued a press release this afternoon, which provided operational highlights and reported our financial results for the quarter ending March 31, 2019. The press release can be found on the Investor Relations section of our website. During our call today, we'll provide an operational update on our GI and microbiome-focused clinical programs and summarize our financial results. We'll take questions after our prepared remarks. In addition to the phone line, this call is being streamed live via webcast, which will be archived on our website, syntheticbiologics.com, for 90 days. During this call, we will be making forward-looking statements regarding Synthetic Biologics' current expectations and projections about future events. Generally, the forward-looking statements can be identified by terminologies such as may, should, expects, anticipates, intends, plans, believes, estimates and similar expressions. These statements are based on current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, including those set forth in Synthetic Biologics' filings with the SEC, many of which are difficult to predict. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information on this call is provided only as of the date of this call, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained on this conference call on account of new information, future events or otherwise, except as required by law. With that, I'd like to turn the call over to Steve. Steve?

Thanks, Vincent. Good afternoon, everyone and thank you for joining our 2019 first quarter investor conference call. The last several months have been a period of careful planning and key execution for Synthetic Biologics with a focus on the strategic advancement of our GI and microbiome-focused pipeline, while reducing our cash burn by streamlining our workforce and refining our strategy. At the beginning of the year, we detailed our strategy to realign our clinical programs on what we believe to be clear and achievable regulatory and development pathways. And while things may seem quiet at the time, I assure you, we are hard at work positioning our portfolio of clinical programs targeting critical unmet needs in the prevention of life threatening gut microbiome infections and GI disorders for clinical success. Of particular note, we announced the commencement of our collaborative Phase 2b investigator-sponsored clinical study of SYN-010 with our clinical partners Cedars-Sinai Medical Center. We're nearing the establishment of a defined clinical development pathway for potential secondary indication for SYN-004 to reduce the incidents and/or severity of aGVHD and other adverse outcomes in allogeneic HCT recipients. We continue to prepare our SYN-020 intestinal alkaline phosphatase program for an IND and have submitted a request for a pre-IND meeting with the FDA. And we continue to focus on prudent cash management and financial stewardship further extending our cash runway through at least the second quarter of 2020. With that backdrop, I'd like to share more detailed updates on our lead clinical development programs starting with an update on SYN-010. Unlike currently approved and marketed therapies for IBS-C, which provide temporary relief to patients by targeting the symptoms in the disease often at a cost of significant adverse side effects. SYN-010 is designed to target and treat an underlying cause of this…

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.